[go: up one dir, main page]

ZA200100177B - Compositions and methods for treating conditions responsive to estrogen. - Google Patents

Compositions and methods for treating conditions responsive to estrogen.

Info

Publication number
ZA200100177B
ZA200100177B ZA200100177A ZA200100177A ZA200100177B ZA 200100177 B ZA200100177 B ZA 200100177B ZA 200100177 A ZA200100177 A ZA 200100177A ZA 200100177 A ZA200100177 A ZA 200100177A ZA 200100177 B ZA200100177 B ZA 200100177B
Authority
ZA
South Africa
Prior art keywords
estrogen
compositions
methods
conditions responsive
treating conditions
Prior art date
Application number
ZA200100177A
Other languages
English (en)
Inventor
Thompson David Duane
Lee Andrew George
Day Wesley Warren
Rosati Robert Louis
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200100177B publication Critical patent/ZA200100177B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
ZA200100177A 2000-01-12 2001-01-08 Compositions and methods for treating conditions responsive to estrogen. ZA200100177B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17575200P 2000-01-12 2000-01-12

Publications (1)

Publication Number Publication Date
ZA200100177B true ZA200100177B (en) 2002-07-08

Family

ID=22641493

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200100177A ZA200100177B (en) 2000-01-12 2001-01-08 Compositions and methods for treating conditions responsive to estrogen.

Country Status (20)

Country Link
US (2) US6632834B2 (xx)
EP (1) EP1120114B1 (xx)
JP (1) JP2001213776A (xx)
KR (1) KR100402563B1 (xx)
AT (1) ATE345794T1 (xx)
AU (1) AU780142B2 (xx)
CA (3) CA2331053C (xx)
CO (1) CO5271709A1 (xx)
CY (1) CY1106272T1 (xx)
DE (1) DE60124600T2 (xx)
DK (1) DK1120114T3 (xx)
ES (1) ES2274853T3 (xx)
HU (1) HUP0100120A3 (xx)
IL (1) IL140802A (xx)
MY (1) MY133571A (xx)
NZ (1) NZ509321A (xx)
PE (1) PE20011046A1 (xx)
PT (1) PT1120114E (xx)
TW (1) TWI246918B (xx)
ZA (1) ZA200100177B (xx)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6517532B1 (en) 1997-05-15 2003-02-11 Palomar Medical Technologies, Inc. Light energy delivery head
US6916495B2 (en) * 1999-02-24 2005-07-12 Allan Taylor Preparation for regulating lower bowel function
EP1177787A3 (en) * 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
CN101194855B (zh) * 2000-12-28 2013-02-27 帕洛玛医疗技术有限公司 用于皮肤的emr治疗处理的方法和装置
US20080306471A1 (en) * 2000-12-28 2008-12-11 Palomar Medical Technologies, Inc. Methods and devices for fractional ablation of tissue
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
JP2005535370A (ja) 2002-06-19 2005-11-24 パロマー・メディカル・テクノロジーズ・インコーポレイテッド 皮膚および皮下の症状を治療する方法および装置
US8987240B2 (en) * 2002-10-23 2015-03-24 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
BRPI0406596A (pt) * 2003-01-22 2005-12-20 Pfizer Prod Inc Métodos para tratar a dor articular e melhorar o sono utilizando um agonista/antagonista de estrogênio
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
WO2005070403A1 (en) * 2004-01-23 2005-08-04 Creighton University Anti-estrogens and methods of use
US20060020035A1 (en) * 2004-03-11 2006-01-26 Oregon Health & Science University Bone marrow protection with N-acetyl-L-cysteine
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
CA2573185A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CA2578636A1 (en) 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating hepatitis c
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
US7856985B2 (en) 2005-04-22 2010-12-28 Cynosure, Inc. Method of treatment body tissue using a non-uniform laser beam
WO2006116174A2 (en) * 2005-04-22 2006-11-02 University Of Cincinnati Pharmaceutical and therapeutic applications relating to a type 9 adenylyl cyclase
JP2009509140A (ja) * 2005-09-15 2009-03-05 パロマー・メデイカル・テクノロジーズ・インコーポレーテツド 皮膚の光学的判定デバイス
US7586957B2 (en) 2006-08-02 2009-09-08 Cynosure, Inc Picosecond laser apparatus and methods for its operation and use
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
KR20160020584A (ko) * 2007-01-22 2016-02-23 지티엑스, 인코포레이티드 핵 수용체에 결합하는 물질
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US20100087402A1 (en) * 2008-09-29 2010-04-08 Vivus, Inc. Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders
TW201043595A (en) * 2009-03-13 2010-12-16 Organon Nv Tetrahydronaphthalen-2-ol derivatives
US9919168B2 (en) 2009-07-23 2018-03-20 Palomar Medical Technologies, Inc. Method for improvement of cellulite appearance
KR101698238B1 (ko) 2010-06-10 2017-01-19 세라곤 파마슈티컬스, 인크. 에스트로겐 수용체 조정제 및 이의 용도
WO2011159769A2 (en) 2010-06-17 2011-12-22 Aragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
ES2981183T3 (es) * 2010-11-10 2024-10-07 Prokidney Formulaciones inyectables para el aumento de órganos
EP2791132A4 (en) 2011-12-14 2015-08-05 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
US9780518B2 (en) 2012-04-18 2017-10-03 Cynosure, Inc. Picosecond laser apparatus and methods for treating target tissues with same
US10285757B2 (en) 2013-03-15 2019-05-14 Cynosure, Llc Picosecond optical radiation systems and methods of use
PL3355884T3 (pl) 2015-10-01 2021-11-29 Olema Pharmaceuticals, Inc. Tetrahydro-1H-pirydo[3,4-b]indolowe leki antyestrogenowe
AU2016366680B2 (en) 2015-12-09 2021-06-24 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulators
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN120887906A (zh) 2016-05-10 2025-11-04 C4医药公司 用于靶蛋白降解的螺环降解决定子体
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109789143A (zh) 2016-07-01 2019-05-21 G1治疗公司 基于嘧啶的抗增殖剂
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
EA201991622A1 (ru) 2017-01-06 2020-01-23 Г1 Терапьютикс, Инк. Комплексная терапия для лечения рака
JP6899504B2 (ja) * 2017-01-10 2021-07-07 ゼジアン ジャーチ デベロップメント ファーマシューティカルズ リミテッド 膜開始エストロゲンシグナルのラソフォキシフェンでのモジュレーションおよび腫瘍の治療方法
WO2018237026A1 (en) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
IL271543B2 (en) 2017-06-29 2025-01-01 G1 Therapeutics Inc Morphological forms of G1T38 and methods for their production
SG11202008151QA (en) 2018-02-26 2020-09-29 Cynosure Inc Q-switched cavity dumped sub-nanosecond laser
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
CN114302722A (zh) 2019-07-07 2022-04-08 奥列马制药公司 雌激素受体拮抗剂方案
CA3154073A1 (en) 2019-12-20 2021-06-24 Christopher G. Nasveschuk Isoindolinone and indazole compounds for the degradation of egfr
EP4114392A4 (en) 2020-03-05 2024-04-10 C4 Therapeutics, Inc. Compounds for targeted degradation of brd9
EP4192458A4 (en) 2020-08-05 2024-09-04 C4 Therapeutics, Inc. COMPOUNDS FOR TARGETED DEGRADATION OF RET
KR20250055538A (ko) 2022-08-03 2025-04-24 브리스톨-마이어스 스큅 컴퍼니 Ret 단백질을 조정하기 위한 화합물
EP4611900A1 (en) 2022-11-04 2025-09-10 Bristol-Myers Squibb Company Ret-ldd protein inhibitors
KR20250117789A (ko) 2022-11-04 2025-08-05 브리스톨-마이어스 스큅 컴퍼니 Ret-ldd 단백질 분해제
WO2025006753A2 (en) 2023-06-30 2025-01-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060503A (en) * 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
GB2273873A (en) * 1992-12-23 1994-07-06 Univ Sheffield Treatment of psoriasis
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US5441986A (en) 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
FR2745182B1 (fr) 1996-02-22 1998-06-19 Sederma Sa Compositions cosmetiques ou dermopharmaceutiques contenant un extrait de solanum lycocarpum
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
IL120268A0 (en) * 1996-02-28 1997-06-10 Pfizer Use of (E)-1-[4'-(2-alkylaminoethioxy)phenyl]1-(3'-hydroxyphenyl)-2-phenylbut-1-enes in inhibiting pathological conditions
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
IL123195A (en) 1997-02-21 2002-11-10 Akzo Nobel Nv Steroid compounds with anti-pregnancy activity and against bone thinning, preparation and pharmaceutical preparations containing them
JP2001515038A (ja) 1997-08-15 2001-09-18 デューク・ユニバーシティー エストロゲン依存性疾患および障害の予防または治療方法
CO5170459A1 (es) * 1999-06-01 2002-06-27 Pfizer Prod Inc Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos
ATE289300T1 (de) * 1999-12-30 2005-03-15 Signal Pharm Inc Verbindungen und verfahren zur modulation von estrogen rezeptoren
US6509332B2 (en) * 2000-07-06 2003-01-21 Wyeth Methods of treating excessive intraocular pressure
EP1177787A3 (en) * 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts

Also Published As

Publication number Publication date
PE20011046A1 (es) 2001-10-19
CY1106272T1 (el) 2011-10-12
TWI246918B (en) 2006-01-11
EP1120114B1 (en) 2006-11-22
US20010041718A1 (en) 2001-11-15
EP1120114A3 (en) 2003-08-20
IL140802A0 (en) 2002-02-10
AU1367601A (en) 2001-07-19
MY133571A (en) 2007-11-30
KR20010103559A (ko) 2001-11-23
CA2331053C (en) 2005-10-25
JP2001213776A (ja) 2001-08-07
NZ509321A (en) 2002-10-25
EP1120114A2 (en) 2001-08-01
HUP0100120A2 (en) 2002-10-28
CA2331053A1 (en) 2001-07-12
US6632834B2 (en) 2003-10-14
ATE345794T1 (de) 2006-12-15
IL140802A (en) 2006-08-01
HU0100120D0 (en) 2001-03-28
DE60124600T2 (de) 2007-04-05
CA2475393A1 (en) 2001-07-12
ES2274853T3 (es) 2007-06-01
CA2475413A1 (en) 2001-07-12
KR100402563B1 (ko) 2003-10-17
HUP0100120A3 (en) 2004-06-28
PT1120114E (pt) 2007-01-31
CO5271709A1 (es) 2003-04-30
DE60124600D1 (de) 2007-01-04
US20040092506A1 (en) 2004-05-13
DK1120114T3 (da) 2007-02-05
AU780142B2 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
HU0100120D0 (en) Pharmaceutical compositions and methods for treating conditions responsive to estrogen
IL142566A0 (en) Compositions and methods for treating female sexual dysfunction
MY133564A (en) Compositions and methods for treating osteoporosis and lowering cholesterol
NZ325060A (en) Non peptide indole derivative and their use as antagonists of gonadotropin releasing hormone
FR16C0021I2 (fr) Azetidines en tant qu'inhibiteurs de mek et leur utilisation pour le traitement des maladies proliferatives
DE60019964D1 (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide als inhibitoren cyclinabhängiger kinasen
EP1199069A3 (en) Use of an estrogen agonist/antagonist for assessing, improving, or maintaining urogenital health
EP1118323A3 (en) Method of reducing morbidity and the risk of mortality
BG106481A (en) Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumour agents
AU4818000A (en) Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands
BRPI0418245A (pt) nitróxi-derivados de prostaglandina
GEP20115213B (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
EP1074549A3 (en) Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors
WO2002060392A3 (en) Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
WO2004064766A3 (en) Method of treatment of conditions by administration of streptolysin o
EP1613328B8 (en) Use of carbamazepine derivatives for the treatment of agitation in dementia patients
EP2140864A3 (en) Use of GAL3 receptor antagonists for the treatment of depression and / or anxiety and compounds useful in such methods
EP1099446A3 (en) Combination treatment for depression and anxiety containing a CNS-penetrant NK-1 receptor antagonist and an antidepressant or anxiolytic agent
AU6921196A (en) 5-ht3 receptor antagonists for dyskinesia
EP1095655A3 (en) NK-1 receptor antagonists and eletriptan for the treatment of migraine
ES2101646A1 (es) Nuevo compuesto derivado del cromeno.
WO2004034967A3 (en) 2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety
BR9901566A (pt) Análogos cis-delta4 de prostaglandinas como hipotensores oculares